||| Menü 
Startseite
Firmenveranstaltungen, Neuemissionen

10/11
09/11
08/11
07/09
08/09
09/09
10/09
11/09
12/09
01/10
02/10
03/10
Geschäftsberichte, Werbung, Earnings, Marketing, Verordnungen

10/11
09/11
03/09
04/09
05/09
06/09
08/09
09/09
10/09
11/09
12/09
01/10
02/10
Fusionen, Übernahmen

11/11
12/08
01/09
02/09
03/09
04/09
05/09
06/09
07/09
08/09
09/09
10/09
11/09
Personal, Belegschaft, Meldungen zu Produkten

06/08
07/08
08/08
09/08
10/08
11/08
12/08
01/09
02/09
03/09
04/09
05/09
06/09
07/09
08/09

Datenschutz
Impressum
Bankleitzahlen - online.de


MediGene Receives Further European Patent on EndoTAG(TM)-1

Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------




Patent renews coverage and expands the protected territory

Martinsried/Munich, October 5, 2009. The biotech company MediGene AG
(Frankfurt: MDG, Prime Standard, TecDAX) has obtained an extensive
patent (no. 1530465) from the European Patent Office on the
manufacturing process for the drug candidate EndoTAG(TM)-1. The
patent protects the manufacturing process used for EndoTAG(TM)-1,
including the drying step applied, products manufactured by the
specified steps, products with identical properties, as well as
further specified dried cationic liposomal compounds. The term of the
patent "Method of producing a cationic liposomal preparation
comprising a lipophilic compound" ends on June 26, 2023.

Dr. Frank Mathias, Chief Executive Officer of MediGene AG: "This new
patent is extremely important for MediGene and for the
commercialization of EndoTAG(TM)-1. In addition to the good patent
protection which we already possess for the EndoTAG(TM) technology in
general and for EndoTAG(TM)-1 in particular, the manufacturing
process and the dried formulation of our drug candidate are now also
patented. Overall patent protection is renewed for the product in
itself, and the protected territory has been enlarged by a number of
European countries. Whereas EndoTAG(TM)-1 is administered in the form
of a suspension, the drug will be commercialized in the form of a
dried product, so the patent represents a major progress toward our
future plans for commercialization."

About EndoTAG(TM)-1: The drug candidate EndoTAG(TM)-1 selectively
attacks blood vessels needed for the growth of tumors. It is a novel
combination of positively charged liposomes - minute globules of
lipid molecules - and the embedded active substance paclitaxel.
EndoTAG(TM)-1 is targeted to the negatively charged cells that are
lining newly formed tumor blood vessels. Thus only tumor blood
vessels are attacked without any harm to those in healthy tissue. At
the same time EndoTAG(TM)-1 inhibits the development of new blood
vessels, thus suppressing further tumor growth. The drug candidate
has obtained orphan drug designation for Europe and the USA, granting
benefits in the development and commercialization of drugs for the
treatment of rare diseases.
In October 2008 MediGene reported positive results obtained in a
clinical phase II trial of the drug candidate EndoTAG(TM)-1 for the
treatment of pancreatic carcinoma. Since 2007, MediGene has been
conducting another clinical phase II trial in the indication triple
receptor-negative breast cancer, the results of which are expected in
the first six months of 2010.

This press release contains forward-looking statements that involve
risks and uncertainties. The forward-looking statements contained
herein represent the judgment of MediGene as of the date of this
release. These forward-looking statements are no guarantees for
future performance, and the forward-looking events discussed in this
press release may not occur. MediGene disclaims any intent or
obligation to update any of these forward-looking statements.
MediGene(TM) and EndoTAG(TM) are trademarks of MediGene AG. This
trademark may be held or licensed for specific countries.

- ends -

MediGene AG is a publicly listed (Frankfurt: MDG, Prime Standard,
TecDAX) biotechnology company located in Martinsried/Munich, Germany,
with subsidiaries in Oxford, UK and San Diego, USA. MediGene is the
first German biotech company to have drugs on the market, which are
being distributed by partner companies and has several drug
candidates in clinical development, two of which provide significant
sales potential. In addition, the company has numerous projects in
research and pre-clinical development and possesses innovative
platform technologies. MediGene focuses on the research and
development of novel drugs for the treatment of cancer and autoimmune
diseases

Contact MediGene AG
E-mail: investor@medigene.com
Fax: +49 - 89 - 85 65 - 2920
Julia Hofmann / Dr. Nadja Wolf, Public Relations, Tel.: +49 - 89 - 85
65 - 3324
Dr. Georg Dönges, Investor Relations, Tel.: +49 - 89 - 85 65 - 2946



--- End of Message ---

MediGene AG
Lochhamer Strasse 11 Martinsried / München Germany

WKN:
502090; ISIN: DE0005020903 ;
Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in
Bayerische Börse München,
Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr
in Niedersächsische Börse zu Hannover,
Regulierter Markt in Frankfurter Wertpapierbörse;
Copyright © Hugin AS 2009. All rights reserved.



 
 ||| Themen-Infos 
· Mehr zu dem Thema Contracts & Corporate events & IPOs &

Der meistgelesene Artikel zu dem Thema Contracts & Corporate events & IPOs &:
Change on the Board of Directors of Feintool Holding AG

 ||| Artikel Bewertung 
durchschnittliche Punktzahl: 0
Stimmen: 0

Bitte nehmen Sie sich einen Augenblick Zeit, diesen Artikel zu bewerten:

Exzellent
Sehr gut
gut
normal
schlecht



Web site engine's code is Copyright © 2003 by PHP-Nuke. All Rights Reserved. PHP-Nuke is Free Software released under the GNU/GPL license.
Erstellung der Seite: 0.074 Sekunden